5th Annual Pharmaceutical Strategic Pricing Conference

September, 2020 | Philadelphia, PA

5th Annual Pharmaceutical Strategic Pricing Conference
September, 2020 | Philadelphia, PA

Request Invite

WE GUARANTEE 100% PRIVACY, YOUR INFORMATION WILL NOT BE SHARED

“I thought the conference was excellent!  Having a conference tailored to one discipline made each panel and contact relevant.”

Director, Compliance & Legal Affairs
Orexigen

“Great insight to hear payer perspective in contracting and account management and the changing healthcare landscape.”

Channel Liaison
Biogen

“It was definitely an excellent well-rounded opportunity to meet new people, get new ideas, and get an in-depth education on what’s to come with the FDA collaborations.”

Quality Engineer
Centurion Medical Products

“It was very well organized event and high quality, the fact to have an IVD track was also interesting. Thanks, I will recommend the Q1 event!”

Regulatory Affairs – EMEA Regional Head
BIOMERIEUX

“The organization and support staff were fantastic! I’m looking forward to next year.”

Global Business Project Lead
Genentech

About the Conference:

The gap of understanding in the public perception of prescription drug costs has led to a push for transparency in the pricing process, as well as the restructuring of pricing models in an effort to reflect the best value for patients. The current push to implement international price indexing is just one regulation that could ripple across the industry and fundamentally alter the way pricing models are structured. Strategic pricing teams for pharmaceutical manufacturers are tasked with predicting the economic climate under this uncertainty. Without clarity on the regulatory future of the industry, and lacking common definitions of key terms, pricing and contracting experts have had difficulty working with third party partners to implement changes and keep up with external pressure.

Core Topics to be Addressed:

  • HHS perspective on implementation of IPI and forthcoming regulation
  • Harmonizing the definition of value between pharmaceutical pricing entities
  • Global impact of US pricing model shift to international price indexing
  • State-level regulatory push for transparency & indications of federal change

Program Highlights:

  • Participating perspectives from PBMs, Payers, HHS & academic professionals
  • Variety of session formats to encourage discussion & knowledge share
  • Collaborative environment that fosters interactive engagement

Core Topics to be Addressed:

  • HHS perspective on implementation of IPI and forthcoming regulation
  • Harmonizing the definition of value between pharmaceutical pricing entities
  • Global impact of US pricing model shift to international price indexing
  • State-level regulatory push for transparency & indications of federal change

Request Invite

WE GUARANTEE 100% PRIVACY, YOUR INFORMATION WILL NOT BE SHARED

Audience

75 Attendees

All attendees come directly from pharmaceutical and biotech companies

Distinguished Presenters

Speaker recruitment in progress

Networking

Networking time is built into the agenda to allow industry peers to connect and exchange ideas

Open Dialogue and Group Share

Each presentation is followed by 10-15 minutes of open dialogue for questions and exchange of best practices

Share This